- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/725 - T-cell receptors
Patent holdings for IPC class C07K 14/725
Total number of patents in this class: 8313
10-year publication summary
|
193
|
316
|
427
|
606
|
690
|
862
|
1045
|
894
|
798
|
685
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Immatics Biotechnologies GmbH | 1157 |
568 |
| The Trustees of the University of Pennsylvania | 4377 |
243 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2897 |
220 |
| Memorial Sloan-Kettering Cancer Center | 1975 |
146 |
| The Regents of the University of California | 20245 |
141 |
| Autolus Limited | 260 |
126 |
| Board of Regents, The University of Texas System | 5921 |
118 |
| Novartis AG | 10635 |
113 |
| Juno Therapeutics, Inc. | 449 |
108 |
| Regeneron Pharmaceuticals, Inc. | 4417 |
96 |
| Cellectis | 403 |
88 |
| Immunocore Limited | 224 |
88 |
| CRISPR Therapeutics AG | 373 |
85 |
| City of Hope | 1006 |
83 |
| Kite Pharma, Inc. | 412 |
81 |
| Fred Hutchinson Cancer Center | 462 |
77 |
| Lentigen Technology, Inc. | 100 |
75 |
| Adaptimmune Limited | 167 |
69 |
| The Board of Trustees of the Leland Stanford Junior University | 6522 |
61 |
| The General Hospital Corporation | 4793 |
53 |
| Other owners | 5674 |